Clinical trials: BRCA1/2
Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
This randomized pilot clinical trial studies a nanoemulsion formulation of curcumin in reducing inflammatory changes in breast tissue in obese women at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ
- Trial name
- NCT01975363
- Testing
- curcumin, Biomarker analysis, Assessment of Dietary Intake
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ovarian Cancer, Ovarian Neoplasms
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
This is a phase II/III randomized controlled trial to evaluate efficacy of platinum-based chemotherapy vs conventionally prescribed non-platinum monochemotherapy in patients with platinum-resistant ovarian cancer
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Serous Adenocarcinoma, BRCA1 Mutation
- Trial name
- EPITOC (NCT04055038)
- Testing
- Platinum-Based Drug, Conventional chemotherapy
- Where
- Russia
- Volunteers
- 164 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Pancreatic Neoplasms, Peutz-Jegher's Syndrome
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years.
- Conditions
- Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- NCT02309632
- Testing
- Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
- Where
- United States
- Sponsor
- University of Arkansas
BRCA1/2 Negative
Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study
The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients.
- Trial name
- NCT02514499
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies how well veliparib works in treating patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back or does not respond to treatment.
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT01540565
- Testing
- Laboratory Biomarker Analysis, Veliparib
- Where
- 153 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, BRCA1 Mutation
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)
Relationship between the presence of the BRCA mutation (BReast Cancer) and outcomes is unclear in high-risk early breast cancers (BC).
- Conditions
- Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- IMBASSA (NCT04012229)
- Testing
- BRCA mutation
- Where
- France
- Volunteers
- 2,295 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
ATM Gene Mutation, Deleterious BRCA1 Gene Mutation
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
This phase II trial studies how well epacadostat and pembrolizumab work in treating participants with pancreatic cancer that has spread to other places in the body.
- Conditions
- ATM Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Homologous Recombination Deficiency
- Trial name
- NCT03432676
- Testing
- Epacadostat, Pembrolizumab
- Sponsor
- M.D. Anderson Cancer Center
Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy.
- Conditions
- Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma
- Trial name
- NCT00892736
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
- Where
- 7 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
BRCA1 Mutation, BRCA2 Mutation
BRCA Main Home Nutritional Intervention-random Study
Women carrying harmful mutation in BRCA1 or BRCA2 gene are at higher risk to develop breast and/or ovarian cancer than the general population.
- Trial name
- NCT03570125
- Testing
- Prolon
- Where
- Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
BRCA1 Mutation, BRCA2 Mutation
Management of Women With BRCA1/2 Mutation
The aim of this study is to determine general practitionners' role in management of women with BRCA1/2 mutation. This study will be conduct between April 2017 and December 2017 at Montpellier University Hospital on women…
- Trial name
- NCT03211611
- Testing
- Questionnaire given to the two groups
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Montpellier
brca1 Mutation Carrier, brca2 Mutation Carrier
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00986206
- Testing
- Biomarker LPA and HE4
- Where
- United States
- Volunteers
- 525 people
- Sponsor
- Women and Infants Hospital of Rhode Island
brca1 Mutation Carrier, brca2 Mutation Carrier
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Trial name
- NCT01097278
- Testing
- cholecalciferol
- Where
- 360 sites in United States
- Volunteers
- 208 people
- Sponsor
- SWOG Cancer Research Network
Breast Neoplasms, Tomosynthesis
Evaluation of Tomosynthesis for Characterization and the Management of Breast Lesions
Tomosynthesis is an innovative technique developed in digital mammography for obtaining a sectional image of the breast. Mammography has the main disadvantage of being an imaging projection that creates overlays, which eliminates…
- Conditions
- Breast Neoplasms, Tomosynthesis, BRCA1 Protein, BRCA2 Protein
- Trial name
- ETOLE (NCT02959398)
- Testing
- Standard mammography, Standard mammography and tomosynthesis
- Where
- 2 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
BRCA1 Syndrome, BRCA2 Syndrome
Prostate Cancer Screening Among Men With High Risk Genetic Predisposition
This will be a prospective diagnostic trial of screening for prostate cancer among men with genetic predisposition.
- Conditions
- BRCA1 Syndrome, BRCA2 Syndrome, Lynch Syndrome
- Trial name
- NCT02053805
- Testing
- PSA, IPSS questionnaire, DRE (Digital Rectal Examination )
- Where
- 2 sites in Israel
- Volunteers
- 200 people
- Sponsor
- Rabin Medical Center
Breast Cancer Stage IV, Ovarian Cancer
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.
- Conditions
- Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- NCT03032614
- Testing
- Carboplatin, Eribulin, Veliparib
- Sponsor
- The University of Texas Health Science Center at San Antonio
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with cisplatin and vinorelbine ditartrate in treating patients with breast cancer that has returned or spread to other parts of the body.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1, Hereditary Breast/Ovarian Cancer - BRCA2
- Trial name
- NCT01104259
- Testing
- veliparib, cisplatin, vinorelbine tartrate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
BRCA1 Gene Mutation, BRCA2 Gene Mutation
The Link Between BRCA Mutation and Endothelial Function
This study evaluates the effect of BRCA1\&2 mutations on cardiovascular diseases by to comparing the endothelial function of male BRCA mutation carriers with that of age matched non-BRCA mutation carriers.
- Trial name
- NCT02474264
- Testing
- Endothelial function assessment, Cardiovascular biomarkers, Endothelial cells
- Where
- Israel
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
This research study is looking at breast cancer risk in women who are BRCA1/BRCA2 mutation carriers. Studying samples of DNA in the laboratory from women who are BRCA1/BRCA2 mutation carriers may help doctors identify biomarkers…
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma
- Trial name
- NCT00899145
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Gynecologic Oncology Group
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
RATIONALE: A study that evaluates the support of a decision guide used together with genetic counseling may improve communication between mothers undergoing BRCA1/2 testing and their minor-age children.
- Trial name
- NCT00685256
- Testing
- counseling intervention, educational intervention, survey administration
- Where
- 2 sites in United States
- Volunteers
- 245 people
- Sponsor
- Georgetown University
To Determine the Prevalence, Penetrance of BRCA1 and BRCA2 Mutations in Romanian Womens With Breast or Ovarian Cancer
BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival
Primary objective To determine BRCA1 and BRCA2 variants in 250 Romanian women with breast/ovarian cancer selected for likeliness to harbor germline mutations in these genes by specific criteria for high-risk status including age…
- Trial name
- NCT02317120
- Testing
- NGS BRCA 1 and BRCA 2 full sequencing, Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2
- Where
- Romania
- Volunteers
- 250 people
- Sponsor
- Alexandru Eniu